Pacira to Report 2025 Financial Results on Thursday February 26, 2026

Rhea-AI Summary

Pacira (Nasdaq: PCRX) will report fourth-quarter and full-year 2025 financial results after U.S. market close on Thursday, February 26, 2026. A live conference call and webcast will follow at 4:30 p.m. ET.

Investors can pre-register for the call to receive dial-in details and a PIN; a live audio webcast will be available on the company’s Events page at investor.pacira.com. A replay of the webcast will be available on the website for approximately two weeks after the call.

Key Figures

Earnings release date: February 26, 2026 Fiscal year-end: December 31, 2025 Conference call time: 4:30 p.m. ET +1 more

4 metrics

Earnings release date February 26, 2026 Fourth quarter and full-year 2025 results after market close

Fiscal year-end December 31, 2025 Year ended December 31, 2025 for reported results

Conference call time 4:30 p.m. ET Earnings conference call start time on February 26, 2026

Webcast replay duration Approximately two weeks Replay availability period following the earnings call

Market Reality Check

Price: $21.45 Vol: Volume 710,844 is below t...

normal vol

$21.45 Last Close

Volume Volume 710,844 is below the 20-day average of 934,534, suggesting limited trading response ahead of the earnings date. normal

Technical Shares at $21.74 are trading below the $24.09 200-day MA and about 21.35% under the 52-week high of $27.64.

Peers on Argus

PCRX gained 2.31% while close peers showed mixed moves (e.g., COLL -2.8%, HROW +...

PCRX gained 2.31% while close peers showed mixed moves (e.g., COLL -2.8%, HROW +1.35%), indicating stock-specific trading rather than a coordinated sector move.

Common Catalyst At least one peer (COLL) also released an earnings date announcement, pointing to a common reporting-calendar theme rather than a broad sector catalyst.

Historical Context

5 past events · Latest: Feb 09 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	Equity inducement grants	Neutral	+0.3%	Inducement stock options and RSUs granted to new employees under plan.
Jan 28	Board appointment	Positive	+2.7%	Addition of experienced clinical development executive to Board of Directors.
Jan 13	Commercial partnership	Positive	-5.8%	LG Chem agreement to commercialize EXPAREL in select Asia-Pacific markets.
Jan 08	Preliminary revenues	Positive	+0.1%	Preliminary 2025 revenue and product sales figures with share repurchase details.
Jan 07	Conference presentation	Positive	+2.7%	J.P. Morgan Healthcare Conference presentation with webcast access for investors.

Pattern Detected

Recent news has generally aligned with price reactions, with one notable selloff following a positive partnership announcement.

Recent Company History

Over the past months, Pacira issued multiple updates, including inducement equity grants on Feb 09, 2026, a board expansion with Dr. Samit Hirawat on Jan 28, 2026, and an EXPAREL commercialization agreement with LG Chem on Jan 13, 2026. Preliminary 2025 revenue figures were released on Jan 08, 2026, followed by a J.P. Morgan conference appearance on Jan 07, 2026. Today’s earnings-date announcement fits into this steady cadence of operational, strategic, and investor-relations communications.

Market Pulse Summary

This announcement sets the timetable for Pacira’s fourth quarter and full‑year 2025 results, with fi...

Analysis

This announcement sets the timetable for Pacira’s fourth quarter and full‑year 2025 results, with figures due after market close on February 26, 2026 and a 4:30 p.m. ET conference call and webcast. In recent months, the company has issued preliminary revenue data, expanded its board, and signed a commercialization deal, creating a backdrop of steady news. Investors will likely focus on the finalized 2025 numbers and management’s commentary when the full release arrives.

AI-generated analysis. Not financial advice.

BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.

For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.

Investor Contact:

Pacira BioSciences, Inc.
Christian Pedetti, (973) 254-4387
Christian.Pedetti@pacira.com

FAQ

When will Pacira (PCRX) report Q4 and full-year 2025 results?

Pacira will release Q4 and full-year 2025 results after market close on February 26, 2026. According to the company, the results will be followed by a live conference call and webcast at 4:30 p.m. ET for investors and analysts.

How can investors join the Pacira (PCRX) February 26, 2026 earnings call?

Investors may join by pre-registering for the conference call to receive dial-in and PIN details. According to the company, registrants receive access information and can participate live via telephone or listen via the webcast on the Events page.

Where will Pacira (PCRX) host the live webcast for the February 26, 2026 report?

The live webcast will be available on Pacira’s investor Events page at investor.pacira.com. According to the company, a live audio webcast will stream at 4:30 p.m. ET and a replay will be posted for about two weeks afterward.

Will there be a replay of Pacira’s (PCRX) February 26, 2026 conference call?

Yes. According to the company, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call. Interested parties unable to join live can access the replay on the Events page.

Can participants ask questions during Pacira’s (PCRX) February 26, 2026 call and how?

Yes; participants can ask questions by joining the telephone Q&A after pre-registering to receive dial-in and PIN access. According to the company, telephone registrants will be able to participate live in the question-and-answer session.